Skip to main content
NewslettersWatchlist

Biosyent Inc(RX-X)
TSX Venture

Today's Change
Delayed Last Update
Day Low11.000
Day High11.160
Open:11.150
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
GlobeNewswire
BioSyent Announces Agreement to Purchase Tibelia® (tibolone) Assets
AI-generated - The Globe and Mail
Biosyent: Top 25 Undervalued Dividend Stocks on TSX-V (RX)
GlobeNewswire
BioSyent Releases Financial Results for Q2 and H1 2024
GlobeNewswire
BioSyent Declares Third Quarter 2024 Dividend
AI-generated - The Globe and Mail
Biosyent: Stocks Overvalued by Analyst Consensus on TSX-V (RX)
GlobeNewswire
FAX Capital Files Early Warning Report Regarding Disposition of Common Shares of BioSyent Inc.
AI-generated - The Globe and Mail
Biosyent: Stocks Overvalued by Analyst Consensus on TSX-V (RX)
GlobeNewswire
BioSyent In-Licenses Endocrinology Product for Canada
GlobeNewswire
BioSyent Releases Financial Results for Q1 2024
GlobeNewswire
BioSyent Declares Second Quarter 2024 Dividend
GlobeNewswire
BioSyent Schedules Q1 2024 Earnings Release for May 16, 2024
GlobeNewswire
BioSyent to Attend Planet MicroCap Showcase
GlobeNewswire
BioSyent Announces Extension of RepaGyn® and Proktis-M® Agreement
GlobeNewswire
BioSyent to Present at 2024 Bloom Burton & Co. Healthcare Investor Conference
GlobeNewswire
FeraMAX® Named #1 Recommended Iron Supplement in Canada by Pharmacists and Physicians for Ninth Consecutive Year
GlobeNewswire
BioSyent to Present at LD Micro New York Investor Conference
GlobeNewswire
BioSyent Announces Grant of Restricted Share Units
GlobeNewswire
BioSyent Releases Financial Results for Fourth Quarter and Full Year 2023
GlobeNewswire
BioSyent Schedules Fourth Quarter and Full Year 2023 Earnings Release for March 13, 2024
GlobeNewswire
BioSyent Named to 2024 TSX Venture 50
GlobeNewswire
BioSyent Declares First Quarter 2024 Dividend
GlobeNewswire
BioSyent Announces Renewal of Normal Course Issuer Bid

Profile

Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Repagyn, and Tibella.m.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.